Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 9;8(5):968-979.
doi: 10.1016/j.ekir.2023.01.041. eCollection 2023 May.

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

Dana V Rizk  1 , Brad H Rovin  2 , Hong Zhang  3 , Naoki Kashihara  4 , Bart Maes  5 , Hernán Trimarchi  6 , Vlado Perkovic  7 , Matthias Meier  8 , Dmitrij Kollins  8 , Olympia Papachristofi  8 , Alan Charney  9 , Jonathan Barratt  10
Affiliations

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

Dana V Rizk et al. Kidney Int Rep. .

Abstract

Introduction: Targeting the alternative complement pathway (AP) is an attractive therapeutic strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology. Iptacopan (LNP023), a proximal complement inhibitor that specifically binds to factor B and inhibits the AP, reduced proteinuria and attenuated AP activation in a Phase 2 study of patients with IgAN, thereby supporting the rationale for its evaluation in a Phase 3 study.

Methods: APPLAUSE-IgAN (NCT04578834) is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study enrolling approximately 450 adult patients (aged ≥18 years) with biopsy-confirmed primary IgAN at high risk of progression to kidney failure despite optimal supportive treatment. Eligible patients receiving stable and maximally tolerated doses of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) will be randomized 1:1 to either iptacopan 200 mg or placebo twice daily for a 24-month treatment period. A prespecified interim analysis (IA) will be performed when approximately 250 patients from the main study population complete the 9-month visit. The primary objective is to demonstrate superiority of iptacopan over placebo in reducing 24-hour urine protein-to-creatinine ratio (UPCR) at the IA and demonstrate the superiority of iptacopan over placebo in slowing the rate of estimated glomerular filtration rate (eGFR) decline (total eGFR slope) estimated over 24 months at study completion. The effect of iptacopan on patient-reported outcomes, safety, and tolerability will be evaluated as secondary outcomes.

Conclusions: APPLAUSE-IgAN will evaluate the benefits and safety of iptacopan, a novel targeted therapy for IgAN, in reducing complement-mediated kidney damage and thus slowing or preventing disease progression.

Keywords: Factor B; IgAN; alternative complement pathway; eGFR slope; iptacopan (LNP023); proteinuria.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Iptacopan is a proximal complement inhibitor that specifically binds to FB to inhibit the activation of the AP and amplification loop. AP, alternative pathway; FB, Factor B; MAC, membrane attack complex.
Figure 2
Figure 2
Study design of APPLAUSE-IgAN (NCT04578834). The asterisk (∗) denotes the main population only; the population with severe renal impairment (n ∼20) is not depicted. BID, twice daily; R, randomization.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wyatt R.J., Julian B.A. IgA nephropathy. N Engl J Med. 2013;368:2402–2414. doi: 10.1056/NEJMra1206793. - DOI - PubMed
    1. Lai K.N., Tang S.C., Schena F.P., et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2 doi: 10.1038/nrdp.2016.1. - DOI - PubMed
    1. Berthoux F.C., Mohey H., Afiani A. Natural history of primary IgA nephropathy. Semin Nephrol. 2008;28:4–9. doi: 10.1016/j.semnephrol.2007.10.001. - DOI - PubMed
    1. Le W., Liang S., Hu Y., et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27:1479–1485. doi: 10.1093/ndt/gfr527. - DOI - PubMed
    1. Rodrigues J.C., Haas M., Reich H.N. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12:677–686. doi: 10.2215/CJN.07420716. - DOI - PMC - PubMed